This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garcia, A. A. Articles by Oza, A. M. Search for Related Content PubMed PubMed Citation Articles by Garcia, A. A. Articles by Oza, A. M.

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

Agustin A. Garcia, Hal Hirte, Gini Fleming, Dongyun Yang, Denice D. Tsao-Wei, Lynda Roman, Susan Groshen, Steve Swenson, Frank Markland, David Gandara, Sidney Scudder, Robert Morgan, Helen Chen, Heinz-Josef Lenz, Amit M. Oza

From the University of Southern California/Norris Comprehensive Cancer Center, Los Angeles; University of California Davis School of Medicine, Sacramento; City of Hope Comprehensive Cancer Center, Duarte, CA; University of Chicago, Chicago, IL; National Cancer Institute, Bethesda, MD; Juravinski Cancer Center, Hamilton; and the Princess Margaret Hospital, Toronto, Ontario, Canada

Corresponding author: Agustin A. Garcia, MD, University of Southern California, Norris Comprehensive Cancer Center, 1441 Eastlake Ave, MS 34, Los Angeles, CA 90033; e-mail: aagarcia{at}usc.edu

Purpose: Vascular endothelial growth factor (VEGF) plays an important role in the biology of ovarian cancer (OC). Inhibitors of VEGF suppress tumor growth in OC models. Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, suppresses tumor growth, possibly by inhibiting angiogenesis. A phase II trial was conducted to evaluate the antitumor activity and adverse effects of bevacizumab and metronomic oral cyclophosphamide in women with recurrent OC.

Patients and Methods: Patients with measurable disease and prior treatment with a platinum-containing regimen were eligible. Up to two different regimens for recurrent disease were allowed. Treatment consisted of bevacizumab 10 mg/kg intravenously every 2 weeks and oral cyclophosphamide 50 mg/d. The primary end point was progression-free survival at 6 months. Plasma levels of VEGF, E-selectin, and thrombospondin-1 were obtained serially.

Results: Seventy patients were enrolled. The probability of being alive and progression free at 6 months was 56% (± 6% SE). A partial response was achieved in 17 patients (24%). Median time to progression and survival were 7.2 and 16.9 months, respectively. The most common serious toxicities were hypertension, fatigue, and pain. Bevacizumab-related toxicities included four episodes of gastrointestinal perforation or fistula, two episodes each of CNS ischemia and pulmonary hypertension, and one episode each of gastrointestinal bleeding and wound healing complication. There were three treatment-related deaths. Levels of VEGF, E-selectin, and thrombospondin-1 were not associated with clinical outcome.

Conclusion: The combination of bevacizumab and metronomic cyclophosphamide is active in recurrent OC. Further study of this combination is warranted.

Supported by National Cancer Institute Grants No. P30 CA 14089, N01 CM62209, CM17107, CM-17102, and CM62203, and by the Ovarian Cancer Coalition of Greater California. This trial was sponsored by Cancer Therapy Evaluation Program of the National Cancer Institute under the Collaborative Research and Development Agreement between the National Cancer Institute and Genentech Inc.

Presented in part at the 41st and 42nd Annual Meetings of the American Society of Clinical Oncology, Orlando, FL, May 13-15, 2005, and Atlanta, GA, June 2-6, 2006.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				R. S. Kerbel Tumor Angiogenesis N. Engl. J. Med., May 8, 2008; 358(19): 2039 - 2049. [Full Text] [PDF]